Related Experiment Video

Updated: Oct 14, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
08:45

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Published on: April 21, 2022

2.5K

m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance

Chen Chen1,2, Yuying Guo1, Yaxin Guo3,4

  • 1Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Oncology
|November 8, 2021
PubMed

Insights

Cancer cells develop drug resistance through epigenetic changes, including abnormal N6-methyladenosine (m6A) modification. Targeting m6A-modified non-coding RNA offers potential strategies to overcome cancer drug resistance.

Area of Science:

  • Molecular Oncology
  • Epigenetics
  • RNA Biology

Background:

  • Cancer drug resistance presents a significant challenge in therapy.
  • Epigenetic alterations, particularly N6-methyladenosine (m6A) modification, are implicated in cancer cells' survival under drug pressure.
  • Abnormal m6A modification is observed in drug-resistant cancer cells, affecting RNA fate and metabolism.

Purpose of the Study:

  • To provide an overview of the regulatory mechanisms of m6A-modified non-coding RNA in cancer drug resistance.
  • To discuss the potential clinical applications of targeting m6A-modified non-coding RNA.
  • To highlight the challenges associated with these potential applications.

Main Methods:

  • Literature review and synthesis of existing research on m6A modification in cancer drug resistance.
  • Analysis of the roles of m6A-modified non-coding RNA in regulating RNA stability, localization, and translation.
  • Exploration of the implications of these findings for therapeutic strategies.

Main Results:

  • m6A modification regulates the fate and metabolism of target RNAs, including non-coding RNAs.
  • m6A-modified non-coding RNAs play critical roles in multiple drug-resistant cancer cells.
  • These modifications represent potential targets for overcoming cancer drug resistance.

Conclusions:

  • m6A-modified non-coding RNA is a key player in cancer drug resistance.
  • Targeting m6A-modified non-coding RNA holds promise for novel cancer therapies.
  • Further research is needed to address the challenges in clinical translation.
Keywords:
cancer drug resistancecircRNAlncRNAm6A modificationmiRNA

More Related Videos

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

11.1K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
RNA Stability01:53

RNA Stability

Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
34.1K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.4K